Bristol-Myers Squibb Co vs Jabil Inc — how do they compare? Bristol-Myers Squibb Co trades at $63.7 (market cap $129.94B), while Jabil Inc trades at $362.37 (market cap $37.37B). The key difference: Bristol-Myers Squibb Co is far larger — about 3.5× Jabil Inc's market cap, and Bristol-Myers Squibb Co pays the higher dividend (3.96%). Which is the better fit depends on your goals.
| BMY | JBL | |
|---|---|---|
Market Cap | $129.94B | $37.37B |
Sector | Health | Technology |
52-Week High | $65.89 | $385.50 |
52-Week Low | $42.60 | $192.49 |
Enterprise Value | $163.92B | $39.90B |
Dividend Yield | 3.96% | 0.09% |
Trailing returns across standard periods
Latest headlines on both assets
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →Jabil is a global manufacturing solutions provider for industries including healthcare, automotive, and cloud. It offers comprehensive design, engineering, and supply chain management for complex electronic products.
Read more on JBL →